Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Recurrent Head and Neck Cancer Squamous Cell Carcinoma Markets and Competition Outlook 2026-2030: Personalized Medicine Drives Revenue Growth, Reaching $4.61 Billion by 2030

globenewswire.com
AZN AstraZeneca's acquisition of Fusion Pharmaceuticals for $2.5 billion strengthens its oncology portfolio with advanced radiopharmaceutical options, indicating a positive outlook for its cancer treatment segment. ABBV AbbVie Inc. is mentioned as a key player in the recurrent head and neck cancer market, but the article does not provide specific details about its performance or future prospects within this context. BMY Bristol Myers Squibb is listed as a key player in the recurrent head and neck cancer market. The article does not offer specific sentiment or details regarding their performance or strategy in this area. MRK Merck KGaA is identified as a key player in the recurrent head and neck cancer market. The article does not provide specific details or sentiment regarding their involvement or future outlook.

Recurrent Head and Neck Cancer Squamous Cell Carcinoma Markets and Competition Outlook 2026-2030: Personalized Medicine Drives Revenue Growth, Reaching $4.61 Billion by 2030 Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers comprehensive insights on market size, regional shares, competitor strategies, and future trends.

The global recurrent head and neck cancer squamous cell carcinoma market is experiencing robust growth, projected to expand from $3.32 billion in 2025 to $3.55 billion in 2026 at a CAGR of 7%. Contributing factors include rising cancer incidence, limited frontline treatment efficacy, and early adoption of innovative therapies. This market is set to rise further, reaching $4.61 billion by 2030, with a CAGR of 6.7%. Key growth drivers are next-gen immunotherapies, precision oncology investments, and combination regimens, alongside a focus on survival outcomes.

Personalized medicine is a significant propellant for market expansion. Advances in genomic research, diagnostics, and individual therapy demands foster this healthcare evolution. In February 2024, the U.S. FDA approved 16 new personalized treatments, up from six in 2022. This personalized approach supports genetic profiling and tailored therapeutic strategies that target specific tumor characteristics, enhancing treatment efficacy for recurrent head and neck cancer.

Leading companies are innovating treatment methods, notably within immuno-oncology. These drugs activate the immune system to target cancer cells, exemplified by Aveta Biomics Inc.'s FDA fast-track designation for APG-157. This investigational agent from turmeric targets cancer selectively, potentially reducing reliance on invasive treatments.

In corporate moves, AstraZeneca Plc acquired Fusion Pharmaceuticals Inc. for $2.5 billion in June 2024. This acquisition aims to enhance AstraZeneca's oncology portfolio with advanced radiopharmaceutical options and expand its Canadian operations. Fusion specializes in radiopharmaceuticals for precision oncology.

North America dominated the market in 2025, with regions like Asia-Pacific and Europe following. However, tariffs are impacting this landscape, raising costs for imported pharmaceuticals and delaying advanced therapy access, though they drive local production and research investment.

This market is characterized by dynamic investments and innovations focused on personalized and multimodal treatments. Key players include Roche Holding AG, Merck KGaA, AbbVie Inc., Bristol Myers Squibb, AstraZeneca, and others.

Reasons to Purchase:

Report Scope:

Key Attributes

The companies featured in this Recurrent Head and Neck Cancer Squamous Cell Carcinoma market report include:

For more information about this report visit https://www.researchandmarkets.com/r/rc2qvg

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment